Your browser doesn't support javascript.
loading
Clinical application of bladder MRI and the Vesical Imaging-Reporting and Data System.
Panebianco, Valeria; Briganti, Alberto; Boellaard, Thierry N; Catto, James; Comperat, Eva; Efstathiou, Jason; van der Heijden, Antoine G; Giannarini, Gianluca; Girometti, Rossano; Mertens, Laura; Takeuchi, Mitsuru; Muglia, Valdair F; Narumi, Yoshifumi; Novara, Giacomo; Pecoraro, Martina; Roupret, Morgan; Sanguedolce, Francesco; Santini, Daniele; Shariat, Shahrokh F; Simone, Giuseppe; Vargas, Hebert A; Woo, Sungmin; Barentsz, Jelle; Witjes, J Alfred.
Afiliación
  • Panebianco V; Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy. valeria.panebianco@uniroma1.it.
  • Briganti A; Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
  • Boellaard TN; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Catto J; Academic Urology Unit, University of Sheffield, Sheffield, UK.
  • Comperat E; Department of Pathology, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Hopital Tenon, Paris, France.
  • Efstathiou J; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • van der Heijden AG; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Giannarini G; Urology Unit, Academic Medical Centre "Santa Maria della Misericordia", Udine, Italy.
  • Girometti R; Institute of Radiology, Academic Medical Centre "Santa Maria della Misericordia", Udine, Italy.
  • Mertens L; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Takeuchi M; Department of Radiology, Radiolonet Tokai, Nagoya, Japan.
  • Muglia VF; Department of Medical Images, Radiation Therapy and Oncohematology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil.
  • Narumi Y; Department of Healthcare, Tachibana University, Kyoto, Japan.
  • Novara G; Department of Surgery, Oncology, and Gastroenterology - Urology Clinic, University of Padua, Padua, Italy.
  • Pecoraro M; Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy.
  • Roupret M; Department of Urology, Sorbonne University, AP-HP, Pitié Salpétrière Hospital, Paris, France.
  • Sanguedolce F; Department of Urology, Fundació Puigvert, Autonomous University of Barcelona, Barcelona, Spain.
  • Santini D; Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
  • Shariat SF; Division of Medical Oncology A, Policlinico Umberto I, Rome, Italy.
  • Simone G; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy.
  • Vargas HA; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
  • Woo S; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
  • Barentsz J; IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.
  • Witjes JA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nat Rev Urol ; 21(4): 243-251, 2024 04.
Article en En | MEDLINE | ID: mdl-38036666
Diagnostic work-up and risk stratification in patients with bladder cancer before and after treatment must be refined to optimize management and improve outcomes. MRI has been suggested as a non-invasive technique for bladder cancer staging and assessment of response to systemic therapy. The Vesical Imaging-Reporting And Data System (VI-RADS) was developed to standardize bladder MRI image acquisition, interpretation and reporting and enables accurate prediction of muscle-wall invasion of bladder cancer. MRI is available in many centres but is not yet recommended as a first-line test for bladder cancer owing to a lack of high-quality evidence. Consensus-based evidence on the use of MRI-VI-RADS for bladder cancer care is needed to serve as a benchmark for formulating guidelines and research agendas until further evidence from randomized trials becomes available.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vejiga Urinaria / Neoplasias de la Vejiga Urinaria Límite: Humans Idioma: En Revista: Nat Rev Urol Asunto de la revista: UROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vejiga Urinaria / Neoplasias de la Vejiga Urinaria Límite: Humans Idioma: En Revista: Nat Rev Urol Asunto de la revista: UROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Italia